[go: up one dir, main page]

KR920021517A - 중축 신경계에 활성인 신규의 3-아미노피리다진 유도체, 그의 제조방법 및 이들의 존재하는 약제학적 조성물 - Google Patents

중축 신경계에 활성인 신규의 3-아미노피리다진 유도체, 그의 제조방법 및 이들의 존재하는 약제학적 조성물 Download PDF

Info

Publication number
KR920021517A
KR920021517A KR1019920008304A KR920008304A KR920021517A KR 920021517 A KR920021517 A KR 920021517A KR 1019920008304 A KR1019920008304 A KR 1019920008304A KR 920008304 A KR920008304 A KR 920008304A KR 920021517 A KR920021517 A KR 920021517A
Authority
KR
South Korea
Prior art keywords
group
compound
hydrogen
pharmaceutically acceptable
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019920008304A
Other languages
English (en)
Inventor
뵈르귀그논 쟝-쟈끄
캉 쟝-뽈
죠르쥐 베르무드 까밀레
Original Assignee
삐에르 마레스떼
엘프 사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 삐에르 마레스떼, 엘프 사노피 filed Critical 삐에르 마레스떼
Publication of KR920021517A publication Critical patent/KR920021517A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

내용 없음

Description

중축 신경계에 활성인 신규의 3-아미노피리다진 유도체, 그의 제조방법 및 이들이 존재하는 약제학적 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 하기 일반식(Ⅰ)의 화합물 및 그의 유기산 또는 무기산과의 염.
    상기 식에서, Rv는 직쇄 또는 측쇄 C1-C4알킬기이고; -R6은 수소, C1∼3알콕시 또는 히드록실기이며; -Z는 하기 일반식의 기이다.
    (상기 식에서,*n1및 n2는 각각 0 또는 1이고,*Y1및 Y2는 각각 수소 또는 C1∼C3알킬기이며;*Y1또는 Y2가 수소 이외의 기라면 T는 알킬이 C1∼C3인 디알킬아미노기이거나, 다음과 같이 선택되는 헤테로사이클이다;
    a)n1=n2=1 Y1=CH3이고 Y2=H 또는 Y1=H이고 Y2=CH3및 W가 산소 또는 황 원자인 경우.
    b)n1=n2=1 Y1=Y2=H 및 p가 2 또는 3인 경우.
    c)n1=n2=0 p가 2 또는 3 및 R=C1∼C3알킬인 경우.
    d)n1=1, n2=0 Y1=H p' 및 p"가 3 또는 4인 경우.
  2. 제1항에 있어서, n1및 n2가 1이고, T가 디알킬아미노기(알킬은 C1∼C3이다)이며, Y1또는 Y2가 수소이외의 기인 화합물 또는 그의 약제학적 허용 가능염.
  3. 제1항에 있어서, n1및 n2가 1이고, Y1이 메틸이고, Y2가 수소이거나, Y1이 수소이고, Y2가 메틸이며, T가 모르폴리노기 또는 티오모르폴리노기인 화합물 또는 그의 약제학적 허용 가능염.
  4. 제1항에 있어서, Z-NH-가 N-8-아자비시클로[3,2,1]옥틸에틸아미노기를 나타내는 화합물 또는 그의 약제학적 허용 가능염.
  5. 제1항에 있어서. Z-NH-가 N-8-에틸 아자비시클로[3,2,1]옥틸-37아미노기를 나타내는 화합물 또는 그의 약제학적 허용 가능염.
  6. 제1항에 있어서, Z-NH-가 1-아자비시클로[3,3,0]옥틸-2-메틸아미노기를 나타내는 화합물 또는 그의 약제학적 허용 가능염.
  7. 하기 일반식(Ⅱ)의 아민을 하기 일반식(Ⅲ)의 3-클로로피리다진과 반응시키고,
    (상기식에서, Z, Rv및 R6은 제1항에서 정의한 바와 같다) 원한다면, 생성된 화합물을 무기산 또는 유기산과의 염으로 전환시킴을 특징으로 하는, 제1항에 따른 화합물의 제조방법.
  8. 제1항 내지 6항에 따른 일반식(Ⅰ)의 화합물을 활성 성분으로서 약제학적 조성물.
  9. 제8항에 있어서, 활성 성분을 하나 이상의 약제학적 부형제와 혼합한 사용단위 형태인 약제학적 조성물.
  10. 제9항에 있어서, 0.5∼100mg의 활성 성분을 함유하는 약제학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920008304A 1991-05-16 1992-05-16 중축 신경계에 활성인 신규의 3-아미노피리다진 유도체, 그의 제조방법 및 이들의 존재하는 약제학적 조성물 Withdrawn KR920021517A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9105973 1991-05-16
FR9105973A FR2676444B1 (fr) 1991-05-16 1991-05-16 Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.

Publications (1)

Publication Number Publication Date
KR920021517A true KR920021517A (ko) 1992-12-18

Family

ID=9412856

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920008304A Withdrawn KR920021517A (ko) 1991-05-16 1992-05-16 중축 신경계에 활성인 신규의 3-아미노피리다진 유도체, 그의 제조방법 및 이들의 존재하는 약제학적 조성물

Country Status (23)

Country Link
US (1) US5276036A (ko)
EP (1) EP0514277B1 (ko)
JP (1) JPH0673021A (ko)
KR (1) KR920021517A (ko)
AT (1) ATE115569T1 (ko)
AU (1) AU656770B2 (ko)
BR (1) BR9201854A (ko)
CA (1) CA2068770A1 (ko)
CZ (1) CZ282531B6 (ko)
DE (1) DE69200895T2 (ko)
DK (1) DK0514277T3 (ko)
ES (1) ES2065755T3 (ko)
FI (1) FI922235L (ko)
FR (1) FR2676444B1 (ko)
GR (1) GR3015389T3 (ko)
HU (2) HUT61305A (ko)
IE (1) IE66926B1 (ko)
IL (1) IL101885A (ko)
MX (1) MX9202282A (ko)
NO (1) NO180233C (ko)
NZ (1) NZ242760A (ko)
RU (1) RU2088577C1 (ko)
TW (1) TW227997B (ko)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631255A (en) * 1989-02-07 1997-05-20 Sanofi Pyridazine derivatives
US5461053A (en) * 1989-02-07 1995-10-24 Sanofi Pyridazine derivatives
JP2983141B2 (ja) * 1993-10-06 1999-11-29 株式会社三和化学研究所 新規化合物及び該化合物を有効成分とする脳機能改善剤
GB9707693D0 (en) * 1997-04-16 1997-06-04 Smithkline Beecham Plc Novel method of treatment
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
PT1284974E (pt) * 2000-05-26 2004-06-30 Pfizer Derivados de triazoliltropano como moduladores de ccr5
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
US8265724B2 (en) * 2007-03-09 2012-09-11 Nellcor Puritan Bennett Llc Cancellation of light shunting
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
GB2579747B8 (en) 2017-08-04 2022-10-05 Skyhawk Therapeutics Inc Methods and compositions for modulating splicing
CA3090130A1 (en) * 2018-02-02 2019-08-08 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
CN114007612A (zh) * 2019-02-05 2022-02-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
WO2020163405A1 (en) 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
WO2020163541A1 (en) * 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
KR20210135239A (ko) * 2019-02-05 2021-11-12 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
CN113677344A (zh) 2019-02-06 2021-11-19 斯基霍克疗法公司 用于调节剪接的方法和组合物
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
US11129829B2 (en) 2019-06-17 2021-09-28 Skyhawk Therapeutics, Inc. Methods for modulating splicing
EP4289823A4 (en) * 2021-02-08 2025-02-26 Medshine Discovery Inc SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2510998B1 (fr) * 1981-08-07 1986-01-10 Sanofi Sa Nouveaux derives amines de la pyridazine, leur procede de preparation et les medicaments, a action desinhibitrice, qui en comportent
FR2539741A1 (fr) * 1983-01-21 1984-07-27 Sanofi Sa Composes a noyau heterocyclique diazote, leur procede de preparation et les medicaments, actifs sur le systeme nerveux central, qui en contiennent
FR2540113A1 (fr) * 1983-01-27 1984-08-03 Sanofi Sa Acides derives de la pyridazine actifs sur le systeme nerveux central
FR2642648B1 (fr) * 1989-02-07 1991-06-21 Sanofi Sa Utilisation de derives d'alkyl-5 pyridazine comme medicaments actifs sur le systeme cholinergique
FR2663326B2 (fr) * 1989-11-17 1992-10-16 Sanofi Sa Derives de la pyridazine, procede de preparation et compositions pharmaceutiques en contenant.
PT93060B (pt) * 1989-02-07 1995-12-29 Sanofi Sa Processo para a obtencao de derivados de piridazina e de composicoes farmaceuticas que os contem
FR2665442B1 (fr) * 1990-07-31 1992-12-04 Sanofi Sa Derives d'alkyl-6 pyridazine, procede de preparation et compositions pharmaceutiques en contenant.
GB8911158D0 (en) * 1989-05-16 1989-07-05 Janssen Pharmaceutica Nv Antiviral pyridazinamines

Also Published As

Publication number Publication date
CZ147392A3 (en) 1993-03-17
FR2676444A1 (fr) 1992-11-20
NO180233C (no) 1997-03-12
HU211920A9 (en) 1996-01-29
IE66926B1 (en) 1996-02-07
AU656770B2 (en) 1995-02-16
MX9202282A (es) 1992-12-01
CA2068770A1 (en) 1992-11-17
JPH0673021A (ja) 1994-03-15
HU9201626D0 (en) 1992-08-28
AU1627492A (en) 1992-11-19
EP0514277B1 (fr) 1994-12-14
FI922235L (fi) 1992-11-17
RU2088577C1 (ru) 1997-08-27
US5276036A (en) 1994-01-04
EP0514277A1 (fr) 1992-11-19
CZ282531B6 (cs) 1997-08-13
BR9201854A (pt) 1993-01-05
ES2065755T3 (es) 1995-02-16
HUT61305A (en) 1992-12-28
ATE115569T1 (de) 1994-12-15
NZ242760A (en) 1994-12-22
GR3015389T3 (en) 1995-06-30
DE69200895D1 (de) 1995-01-26
TW227997B (ko) 1994-08-11
FI922235A0 (fi) 1992-05-15
NO921949L (no) 1992-11-17
IL101885A (en) 1996-08-04
DE69200895T2 (de) 1995-06-29
NO921949D0 (no) 1992-05-15
IL101885A0 (en) 1992-12-30
NO180233B (no) 1996-12-02
DK0514277T3 (da) 1995-05-01
FR2676444B1 (fr) 1995-03-10
IE921557A1 (en) 1992-11-18

Similar Documents

Publication Publication Date Title
KR920021517A (ko) 중축 신경계에 활성인 신규의 3-아미노피리다진 유도체, 그의 제조방법 및 이들의 존재하는 약제학적 조성물
KR890000470A (ko) 2,2-디메틸크로만-3-올 유도체, 그의 제조방법 및 그를 함유하는 약학 조성물
AU1085492A (en) New n-myristoyltransferase inhibitors, process for preparing these and pharmaceutical compositions containing them
KR900006296A (ko) 이미다졸린 유도체 및 그의 제조방법
KR930016436A (ko) 4, 13-디옥사바이사이클로[8.2.1]트리데세논유도체와 그의 제조방법, 그의 제조를 위한 중간체 및 이화합물이 함유된 약학조성물
KR910009672A (ko) 피리다진 유도체, 이의 제조방법 및 이것을 함유하는 약학 조성물
KR930000508A (ko) 2-아미노피리미딘-4-카르복시아미드 유도체 그 제법 및 치료에의 이용
ATE73449T1 (de) 2-piperazinyl-2-oxo-aethylensubstituierte flavonoid-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammenstellungen.
KR910016689A (ko) 우레아 유도체 및 이의 염, 이를 함유하는 약제학적 조성물 및 이의 제조방법
AU2291583A (en) Dialkylaminoalkyoxybenzylalcohol derivatives
KR900016178A (ko) 2-치환 n,n&#39;-디트리메톡시벤조일 피페라진, 그의 제조 방법 및 그를 함유하는 치료 조성물
KR880000432A (ko) 4(3H)-옥소-5,6,7,8-테트라히드로피리도-2,3-d 피리미딘 유도체
AU579665B2 (en) 2-pyridine-thiol derivatives
SE8804696L (sv) Dioxazocin- derivat, deras framstaellning och beredningar innehaallande desamma
KR920002550A (ko) 6-알킬피리다진 유도체, 그의 제법 및 그를 함유하는 약학 조성물
FI851456A0 (fi) Foerfarande foer framstaellning av 1-cyklohexyl-3,4-dihydroisokinolinderivat.
KR920002564A (ko) N-알킬 티아졸리딘 유도체
ATE36154T1 (de) 4-phenylaminopyridin-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
KR920002613A (ko) 이환성 함유 황화합물
KR880007502A (ko) 신규의 아미노알카노일-디벤조[d, g][1,3,6]디옥사조신 및 그의 제조방법
KR880006251A (ko) 개선된 약물 동태학적 성질을 갖는 신규의 세팔로스포린 유도체류, 그의 제조방법 및 그를 함유한 약학 조성물
ES485333A1 (es) Procedimiento para preparar derivados 5,6,7,8-tetrahidro-4 (3h)-quinazolinonicos y sus sales
KR980002035A (ko) 비페닐 유도체 및 그의 제조방법 및 그를 함유한 약제 조성물
KR950008520A (ko) 세팔로스포린 유도체 및 그의 제조방법

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19920516

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid